Arkolith/Insider Trading/IBRX/Form 4

Sachs David C.

Chief Financial OfficerImmunityBio, Inc. (IBRX) · full profile →Form 4 · filed Feb 24, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 22, 2026Tax withholding(F)21K$8.70$180K300K
Feb 22, 2026Option exercise(M)41K—$0321K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 22, 2026Option exercise(M)41K—$041K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001848899-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML